OncoMatch/Clinical Trials/NCT07223424
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Is NCT07223424 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including nivolumab and pembrolizumab for renal cell carcinoma.
Treatment: nivolumab · pembrolizumab — The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Melanoma
Colorectal Cancer
Hepatocellular Carcinoma
Esophageal Carcinoma
Cervical Cancer
Gastric Cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07223424 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify